Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent~* Mentally stable and able to comply with the procedures of the study protocol~* Clinical history compatible with type 1 diabetes diagnosed less than 10 days of enrolment Stimulate c-peptide \>0.1 nmol/l~Exclusion Criteria:~* Patients with BMI\>30~* Patients with unstable cardiovascular status~* Patients with active infections, unless treatment is not judged necessary by the investigators~* Patients with serological evidence of infection with HIV, hepatitis B or hepatitis C.~* Sexually active females who are not a) postmenopausal, b) surgically sterile or c) using an acceptable method of contraception: oral contraceptives, Norplant, Depo-provera and barrier devices combined with spermicidal gel are acceptable.~* Patients with known or previous malignancy. Patient with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with autologous MSC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stem cells (Type: ACTIVE_COMPARATOR): Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus.
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).